ArticleInfection and immunity2011
Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.
Article in Infection and immunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Dual-targeting oral nanoparticle mucosal vaccine against brucella infection: co-targeting M cells and dendritic cells.Journal of nanobiotechnology · 2026Article
- Identifying Two New Ros/MucR Proteins: An Atypical Structure with a Divergent Function.Biomolecules · 2026Article
- Breaking the silence-role of MucR as a virulence determinant inJournal of bacteriology · 2025Review
- Review
- Evaluation of Brucellosis Vaccines: A Comprehensive Review.Frontiers in veterinary science · 2022Review
- Uncovering the Hidden Credentials ofMicrobiology and molecular biology reviews : MMBR · 2021Review
- The Transcriptional Regulator MucR, but Not Its Controlled Acid-Activated Chaperone HdeA, Is Essential for Virulence and Modulates Surface Architecture and Properties inFrontiers in veterinary science · 2021Article
- Deletion of the Transcriptional Regulator MucR inFrontiers in veterinary science · 2021Article
- Article
- Different Impacts of MucR Binding to theBiomolecules · 2020Article
- Ancestral zinc-finger bearing protein MucR in alpha-proteobacteria: A novel xenogeneic silencer?Computational and structural biotechnology journal · 2020Review
- MucR binds multiple target sites in the promoter of its own gene and is a heat-stable protein: Is MucR a H-NS-like protein?FEBS open bio · 2018Article
- Development and trial of vaccines againstJournal of veterinary science · 2017Review
- The Case for Live Attenuated Vaccines against the Neglected Zoonotic Diseases Brucellosis and Bovine Tuberculosis.PLoS neglected tropical diseases · 2016Review
- Protection Provided by an Encapsulated Live Attenuated ΔabcBA Strain of Brucella ovis against Experimental Challenge in a Murine Model.Clinical and vaccine immunology : CVI · 2015Article
- Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions.The American journal of pathology · 2015Review
- Coordinated zinc homeostasis is essential for the wild-type virulence of Brucella abortus.Journal of bacteriology · 2015Article
- Quantitative analysis of the Brucella suis proteome reveals metabolic adaptation to long-term nutrient starvation.BMC microbiology · 2013Article
- Article
- Diverse genetic regulon of the virulence-associated transcriptional regulator MucR in Brucella abortus 2308.Infection and immunity · 2013Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Brucellosis is a zoonosis of nearly worldwide distribution. Vaccination against this pathogen is an important control strategy to prevent the disease. Currently licensed vaccine strains used in animals are unacceptable for human use due to undesirable side effects and modest protection. Substantial progress has been made during the past 10 years toward the development of improved vaccines for brucellosis. In part, this has been achieved by the identification and characterization of live attenuated mutants that are safer in the host but still can stimulate an adequate immune response. In the present study, the identification and characterization of the mucR mutant (BMEI 1364) as a vaccine candidate for brucellosis was conducted. BALB/c mice were vaccinated intraperitoneally at a dose of 10(5) CFU with the mutant to evaluate safety and protective efficacy against intraperitoneal and aerosol challenge. All animals vaccinated with the vaccine candidate demonstrated a statistically significant degree of protection against both intraperitoneal and aerosol challenge. Safety was revealed by the absence of Brucella associated pathological changes, including splenomegaly, hepatomegaly, or granulomatous disease. These results suggest that the 16MΔmucR vaccine is safe, elicits a strong protective immunity, and should be considered as a promising vaccine candidate for human use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.